免疫性血小板减少症患者对mRNA新冠疫苗的体液免疫应答
在28例免疫性血小板减少症(ITP)患者中测量接种mRNA新冠疫苗后的抗SARS-CoV-2刺突抗体滴度,ITP患者血清转换率为91.3%,与健康对照相当,但抗体滴度显著低于健康对照且随年龄增长而下降,接种后任意时间点接受泼尼松龙最低剂量至少5 mg/天的患者抗体滴度低于其他患者。
要点
- ITP患者接种mRNA新冠疫苗后血清转换率为91.3%,与健康对照相当。
- ITP患者抗体滴度显著低于健康对照,且随年龄增长而下降。
- 接种后任意时间点泼尼松龙最低剂量≥5 mg/天的ITP患者抗体滴度低于其他患者。
核心结论
- ITP患者接种mRNA新冠疫苗后血清转换率与健康对照相当,但抗体滴度显著低于健康对照且随年龄增长而下降。
- 接种后任意时间点接受泼尼松龙最低剂量至少5 mg/天的ITP患者抗体滴度低于其他患者。
研究设计与样本
- 研究纳入28例ITP患者,接种mRNA新冠疫苗后测量抗SARS-CoV-2刺突抗体滴度,并与健康对照比较。
主要发现
- ITP患者血清转换率为91.3%,与健康对照相当。
- ITP患者抗体滴度显著低于健康对照,且随年龄增长而下降。
- 接种后任意时间点泼尼松龙最低剂量至少5 mg/天的ITP患者抗体滴度低于其他患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Data for COVID-19 vaccine response in patients with immune thrombocytopenia (ITP) are very limited. In a study of 28 patients with ITP, anti-severe acute respiratory syndrome coronavirus 2 spike antibody titres were measured after vaccination. The seroconversion rate for ITP patients was 91.3%, comparable to that in healthy controls (HCs). However, the antibody titre in ITP patients was significantly lower than that in HCs and declined with ageing. Furthermore, the antibody titre in ITP patients who received a minimum prednisolone dose of at least 5 mg/day at any time-point at or after initial vaccination was lower than that in other patients.
引用
- Mori A, Onozawa M, Kobayashi M, et al. Humoral response to mRNA-based COVID-19 vaccine in patients with immune thrombocytopenia. Br J Haematol. 2022. PMID: 36442510. doi:10.1111/bjh.18578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。